The milestone was earned when Arrowhead achieved the second development milestone event in a Phase 1/2 clinical study of ...
Arrowhead Pharmaceuticals' fair value estimate has recently risen from $47.50 to $55.00 per share, signaling an improved outlook following the FDA approval of Redemplo. This updated price target ...
As of Wednesday, November 26, Arrowhead Pharmaceuticals, Inc.’s ARWR share price has surged by 9.30%, which has investors ...
18h
Arrowhead Pharmaceuticals (ARWR) Is Up 48.1% After First FDA Approval for siRNA Rare Disease Therapy
In November 2025, Arrowhead Pharmaceuticals announced that the U.S. FDA approved REDEMPLO (plozasiran) as the first and only siRNA treatment for adults with familial chylomicronemia syndrome, ...
Arrowhead Pharmaceuticals (ARWR) has just gained FDA approval for REDEMPLO, its first-ever approved drug and the first siRNA therapy available for familial chylomicronemia syndrome. This regulatory ...
Which Is a Better Investment, Arrowhead Pharmaceuticals, Inc. or BioMarin Pharmaceutical Inc. Stock?
Learn more about whether Arrowhead Pharmaceuticals, Inc. or BioMarin Pharmaceutical Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
Q4 2025 Earnings Call Transcript November 25, 2025 Arrowhead Pharmaceuticals, Inc. misses on earnings expectations. Reported ...
Arrowhead Pharmaceuticals faces key FDA decisions, legal challenges, and trial results. Read the latest analysis on the stock ...
The clearance of Redemplo for a rare genetic disorder marks Arrowhead’s transition, after two decades, into a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback